|
|
 |
|
Viewing report
|
|
|
|
Chemotherapy-Induced Neutropenia (CIN) Therapeutics -Pipeline Assessment and Market Forecasts to 2018
GlobalData, Nov 2011, Pages: 95
Chemotherapy-Induced Neutropenia (CIN) Therapeutics -Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Chemotherapy-Induced Neutropenia (CIN) Therapeutics -Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global CIN therapeutics market. The report identifies the key trends shaping and driving the global CIN therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CIN sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimates that the global Chemotherapy-induced Neutropenia (CIN) therapeutics market was valued at $3.6 billion in 2005 and grew at a Compound Annual Growth Rate (CAGR) of 5.8% to reach $4.8 billion in 2010. The market is forecast to grow at a CAGR of 2.3% over the next eight years to reach $5.8 billion by 2018. This decline in growth rate is primarily attributed to the expected patent expiry of Neupogen in 2013 (2006 in Europe) and Neulasta in 2015 which will make way for the entry of biosimilars (generic version of biologics) into the market. The increase in prescription population will help in partially offsetting the revenue loss due to the patent expiries.
Scope
The report provides information on the key drivers and challenges of the CIN market. Its scope includes -
- Analysis of seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan), with CIN market revenues data from 2005 to 2010, and forecasts to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as long acting recombinant PEGylated G-CSFs, long-acting recombinant human albumin-G-CSFs, long acting glyco-PEGylated recombinant human G-CSFs, long-acting recombinant GM-CSFs, allogeneic cell-based therapies, recombinant fusion protein G-CSFs, neutrophil stimulators, recombinant protease inhibitors and hematopoeitic stem cell stimulators.
- Analysis of the current and future competition in the global CIN therapeutics market. Key market players covered are Eurofarma Laboratorios Ltda, Green Cross Corporation in collaboration with Symyoo, Intas Biopharmaceuticals Ltd. in collaboration with Apotex Inc. and Teva Pharmaceuticals.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the CIN therapeutics market.
- Analysis of key recent licensing and partnership agreements in CIN therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global CIN market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global CIN therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global CIN therapeutics market landscape? – Identify, understand and capitalize
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
|
|
|
|
